InvestorsHub Logo
Followers 0
Posts 1200
Boards Moderated 0
Alias Born 05/05/2017

Re: None

Wednesday, 10/24/2018 4:04:08 PM

Wednesday, October 24, 2018 4:04:08 PM

Post# of 44784
"Beyond the startup capital, Celularity says it can count on revenue from Biovance and Interfyl, tissue repair strips and drips Hariri developed years ago, which the company just spent $29 million to buy back from another biotech company. Celularity says the two products will bring in at least $25 million this year, and it expects an additional $15 million or more from its stem cell collection arm, which it describes as “the world’s only repository of private and publicly donated placenta cells and biomaterials.” (The money comes from customers who pay Celularity to bank their samples.)"

https://www.bloomberg.com/news/articles/2018-02-15/no-really-save-that-placenta